Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BAY1093884 in Severe Hemophilia
NCT03481946Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of befovacimab in hemophilia A and hemophilia B (HB), sponsored by Bayer. Primary endpoints: Area Under the Curve (0-tlast) at 15 days, Dose-normalized Area Under the Curve at 15 days and 2 more. Started May 2018; status: completed.
02
Drugs
befovacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03481946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03481946.